First-in-human Folate Receptor alpha-targeted BiTE-secreting T cells ovarian cancer clinical trial

Project summary

This proposal will evaluate the safety and feasibility of treating relapsed ovarian cancer (OC) using a novel adoptive T cell therapy (BiTE-secreting T cells). This therapy represents a bench-to-bedside approach to improve clinical outcomes for OC patients who develop treatment refractory cancer. This Phase 1 trial will be complemented by mechanistic studies designed to assess therapy-driven changes associated with clinical response. Findings from this first-in-human study will support submission of new collaborative MPI grants to enroll additional OC patients in an expansion trial using BiTE-secreting T cells, with the goal of identifying an effective therapeutic option for OC patients.

This grant was made possible in part by a generous donation from The Edmée Firth Fund for Research in Ovarian Cancer (EFFROC).